INVANZ Drug Patent Profile
✉ Email this page to a colleague
When do Invanz patents expire, and when can generic versions of Invanz launch?
Invanz is a drug marketed by Msd Sub Merck and is included in one NDA.
The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ertapenem sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Invanz
A generic version of INVANZ was approved as ertapenem sodium by ACS DOBFAR SPA on April 16th, 2018.
Summary for INVANZ
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 58 |
| Clinical Trials: | 21 |
| Patent Applications: | 5,049 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for INVANZ |
| What excipients (inactive ingredients) are in INVANZ? | INVANZ excipients list |
| DailyMed Link: | INVANZ at DailyMed |
Recent Clinical Trials for INVANZ
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Todd C. Lee MD MPH FIDSA | Phase 2 |
| Iterum Therapeutics, US Limited | Phase 3 |
| Iterum Therapeutics, International Limited | Phase 3 |
Pharmacology for INVANZ
| Drug Class | Penem Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for INVANZ
Paragraph IV (Patent) Challenges for INVANZ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| INVANZ | Injection | ertapenem sodium | 1 g/vial | 021337 | 1 | 2012-12-21 |
US Patents and Regulatory Information for INVANZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INVANZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Msd Sub Merck | INVANZ | ertapenem sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 021337-001 | Nov 21, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INVANZ
See the table below for patents covering INVANZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | T66514 | ⤷ Try a Trial | |
| Taiwan | 434014 | ⤷ Try a Trial | |
| European Patent Office | 0863901 | ANTIBIOTIQUE A BASE DE CARBAPENEM, SA COMPOSITION ET SON PROCEDE DE PREPARATION (CARBAPENEM ANTIBIOTIC, COMPOSITION AND METHOD OF PREPARATION) | ⤷ Try a Trial |
| Georgia, Republic of | P20022694 | Carbapenems Containing a Carboxy Substituted Phenyl Group, Processes for Their Preparation, Intermediates and Use as Antibiotics | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INVANZ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0579826 | 10299041 | Germany | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON, EINSCHLIESSLICH ERTAPENEM-NATRIUM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418 |
| 0579826 | 36/2002 | Austria | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEM UND ALLE PHARMAZEUTISCH ANNEHMBAREN SALZE DAVON, INSBESONDERE NATRIUM-ERTAPENEM; REGISTRATION NO/DATE: EU/1/02/216/001 20020418 |
| 0579826 | CA 2002 00025 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEM OG FARMACEUTISK ACCEPTABLE SALTE DERAF |
| 0579826 | SPC/GB02/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
